Scholar Rock Charts Path to Apitegromab Approval

Scholar Rock Holding ((SRRK)) has held its Q1 earnings call. Read on for the main highlights of the call.

Scholar Rock’s latest earnings call struck an upbeat tone, with management emphasizing decisive regulatory progress and a bolstered balance sheet. The acceptance of its apitegromab BLA, dual manufacturing paths, and advancing European review underpinned a narrative of growing momentum, even as executives acknowledged ongoing manufacturing, regulatory, and spending risks.

FDA Acceptance of Apitegromab BLA Sets Clear Path

The FDA accepted Scholar Rock’s biologics license application for apitegromab in children and adults with spinal muscular atrophy and set a PDUFA action date of September 30, 2026. The filing includes two independent fill‑finish facilities, which management framed as a critical risk‑mitigation step for eventual approval.

Dual Fill‑Finish Strategy Strengthens Supply Security

All drug product needed for the FDA review has been supplied by a second U.S. fill‑finish site, which the company expects will deliver ample commercial supply in early Q3 2026. In parallel, the FDA completed an unannounced reinspection of Catalent Indiana, and regulators now have up to 90 days to classify the site, giving Scholar Rock multiple supply and approval pathways.

European Review on Track for Late‑2026 Launch

In Europe, the marketing authorization application for apitegromab is progressing, with a CHMP opinion anticipated near mid‑2026. If timelines hold, Scholar Rock aims to begin launching in the second half of 2026, initially targeting Germany as the entry point to the European market.

Cash War Chest and Flexible Financing Levers

The company ended the first quarter with $480 million in cash, cash equivalents, and marketable securities, reflecting recent financing moves. These included a $100 million draw on an existing debt facility and $98 million in net proceeds from an at‑the‑market program, alongside an option to draw another $150 million after approval and plans to monetize a priority review voucher.

Commercial Infrastructure Ready for U.S. Launch

Scholar Rock signaled it is launch‑ready, with a commercial team prepared to move quickly once approval comes. The company reported established reach to roughly 140 SMA centers and about 2,600 prescribing physicians, supported by a patient services platform, an expanded specialty pharmacy network, and partnerships enabling access to more than 10,000 home‑infusion nurses.

Pipeline Progress Beyond Apitegromab

Management highlighted continued pipeline advancement, including ongoing enrollment and dosing in the Phase II OPAL study in infants and toddlers under two years old. A randomized Phase II FORGE trial in facioscapulohumeral muscular dystrophy is slated to start mid‑year with 60 patients, while subcutaneous apitegromab and the SRK‑439 anti‑myostatin program both advance through early‑stage studies.

Large Unmet Need and Addressable SMA Market

Executives underscored the unmet clinical need, noting that roughly 95% of SMA patients continue to suffer progressive muscle atrophy despite SMN‑targeted therapies. Cure SMA data suggest around one‑third of U.S. patients have received at least two SMN‑directed treatments, and Scholar Rock estimates a global pool of up to 35,000 patients who have received at least one such therapy.

Manufacturing Risk Still Tied to Catalent Indiana

Despite progress, manufacturing‑related approvability risk remains, rooted in a prior complete response letter that focused solely on observations at Catalent Indiana. While a reinspection has been completed, the FDA’s classification, expected within 90 days, will be pivotal, and uncertainty persists until regulators formally rule on the facility.

European Approval Contingent on U.S. Manufacturing Clearance

The company cautioned that the EMA’s decision is linked to the FDA’s stance on Catalent Indiana, tying European timelines to U.S. manufacturing outcomes. Management stressed that dialogue with European regulators has been constructive, but the conditional nature of the approval path adds another layer of regulatory dependency.

Funding Operations Without Product Revenue

Scholar Rock reported no product revenue, underscoring its reliance on external capital to finance operations and launch preparations. The company’s strategy leans heavily on debt, equity via the ATM program, and the planned sale of a priority review voucher, highlighting ongoing dependence on capital markets while it remains pre‑commercial.

High Quarterly Spend Ahead of Commercialization

Operating expenses for the first quarter totaled $102 million, including $80 million of noncash stock‑based compensation, with ex‑SBC spending at $84 million. Management framed this as deliberate pre‑launch investment in commercial infrastructure and R&D, but the burn rate underscores the importance of successful approval and commercialization.

Label Scope and Payer Dynamics Still Unknown

The company acknowledged that the ultimate label for apitegromab remains in the hands of regulators, making it premature to predict exact indications or breadth of use. Payer policies will also influence how apitegromab is used alongside existing SMA therapies, adding uncertainty to adoption patterns and peak revenue potential.

FSHD Program Faces Competitive and Scientific Risk

In FSHD, Scholar Rock positioned its FORGE trial as differentiated, even as it recognized heightened risk after Roche and Chugai discontinued their own anti‑myostatin program. The setback for a competitor underscores scientific uncertainty in this indication, making upcoming data a critical proof point for the company’s strategy.

Forward‑Looking Outlook and Key Milestones

Management reiterated its roadmap anchored by the September 30, 2026 PDUFA date and the twin‑site BLA that includes Catalent Indiana and a second U.S. facility expected to supply commercial drug in early Q3 2026. Near‑term milestones include the EMA’s mid‑year CHMP opinion, a targeted H2 2026 European launch, execution of financing options, and continued progress across OPAL, FORGE, subcutaneous apitegromab, and SRK‑439.

Scholar Rock’s earnings call painted the picture of a company leaning into opportunity while managing meaningful risk, with regulatory, manufacturing, and financing threads tightly intertwined. Investors will now watch execution against this dense milestone calendar, as the apitegromab decision timeline and early commercial performance could define the company’s trajectory in the neuromuscular space.